Who to call at Georgiamune, and when
Fundz watches for the moments Georgiamune starts buying, and tells you who to reach.
- An alert the day Georgiamune raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Georgiamune, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Georgiamune. With Fundz connected, it knows.
Menarini and Georgiamune Enter $1.1 Billion License Agreement for Cancer Immunotherapy GIM-621.
Contract Type
agreement
GaithersburgBiotechnologyHealth CareMedicalTherapeuticsDescription
Menarini and Georgiamune have announced a worldwide license and collaboration agreement for GIM-621, a groundbreaking cancer immunotherapy. Georgiamune will receive $45 million in upfront payments, with the total deal potentially reaching $1.1 billion including additional royalties.
Quick answer
Menarini and Georgiamune Enter $1.1 Billion License Agreement for Cancer Immunotherapy GIM-621. (October 25, 2026). Georgiamune is based in Gaithersburg, Maryland, United States.
- What agreement did Georgiamune announce on October 25, 2026?
- Menarini and Georgiamune have announced a worldwide license and collaboration agreement for GIM-621, a groundbreaking cancer immunotherapy. Georgiamune will receive $45 million in upfront payments, with the total deal potentially reaching $1.1 billion including additional royalties.
- What does Georgiamune do?
- Georgiamune Inc. is a clinical-stage science and discovery biotechnology company focused on reprogramming immune signaling pathways to redirect the immune system to fight diseases.
- Where is Georgiamune based?
- Georgiamune is based in Gaithersburg, Maryland, United States.
- Which similar companies announced agreements around the same time?
- Cognito Therapeutics (October 27, 2026), BioMarin Pharmaceutical (October 29, 2026), Alexion (October 29, 2026) and YD Bio Limited (October 20, 2026) also announced agreements within 45 days of Georgiamune.
Source: Fundz verified event record.
Other recent agreements in Medical and Therapeutics
Contracts and agreements at companies in the same sectors within 45 days, from Fundz verified event records.
- Rhode Island Life Science Hub and Cognito Therapeutics launch partnership for Alzheimer's research. (October 27, 2026)
- BioMarin Enters Exclusive License Agreement With GC Biopharma and Hanmi Pharm for HM15421/GC1134A to Treat Fabry Disease. (October 29, 2026)
- Wolves Foundation and Alexion extend partnership to support Wolves Disability FC and Wolves Wishes for three more years. (October 29, 2026)
- YD Bio and EG BioMed Form Partnership with JoiiUp to Launch AI Cancer Risk Assessment for Corporate Wellness. (October 20, 2026)
- GondolaBio and Children’s Tumor Foundation Partner to Enhance Neurofibromatosis Type 1 Program Development. (October 26, 2026)
- Genmab and Incyte collaborate on a colorectal cancer trial using petosemtamab and a mutation-targeting drug. (October 24, 2026)
Related People
Georgiamune signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.